Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 2
2007 1
2010 3
2011 5
2012 14
2013 18
2014 23
2015 21
2016 28
2017 35
2018 22
2019 30
2020 86
2021 111
2022 134
2023 94
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

565 results

Results by year

Filters applied: . Clear all
Page 1
Remdesivir for the Treatment of Covid-19 - Final Report.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Beigel JH, et al. Among authors: ohmagari n. N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8. N Engl J Med. 2020. PMID: 32445440 Free PMC article. Clinical Trial.
Human Gut Microbiota and Its Metabolites Impact Immune Responses in COVID-19 and Its Complications.
Nagata N, Takeuchi T, Masuoka H, Aoki R, Ishikane M, Iwamoto N, Sugiyama M, Suda W, Nakanishi Y, Terada-Hirashima J, Kimura M, Nishijima T, Inooka H, Miyoshi-Akiyama T, Kojima Y, Shimokawa C, Hisaeda H, Zhang F, Yeoh YK, Ng SC, Uemura N, Itoi T, Mizokami M, Kawai T, Sugiyama H, Ohmagari N, Ohno H. Nagata N, et al. Among authors: ohmagari n. Gastroenterology. 2023 Feb;164(2):272-288. doi: 10.1053/j.gastro.2022.09.024. Epub 2022 Sep 23. Gastroenterology. 2023. PMID: 36155191 Free PMC article.
Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.
Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Sakaguchi H, Sonoyama T, Ichihashi G, Sanaki T, Baba K, Tsuge Y, Uehara T. Mukae H, et al. Among authors: ohmagari n. Clin Infect Dis. 2023 Apr 17;76(8):1403-1411. doi: 10.1093/cid/ciac933. Clin Infect Dis. 2023. PMID: 36477182 Free PMC article. Clinical Trial.
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.
Butler MS, Gigante V, Sati H, Paulin S, Al-Sulaiman L, Rex JH, Fernandes P, Arias CA, Paul M, Thwaites GE, Czaplewski L, Alm RA, Lienhardt C, Spigelman M, Silver LL, Ohmagari N, Kozlov R, Harbarth S, Beyer P. Butler MS, et al. Among authors: ohmagari n. Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0199121. doi: 10.1128/AAC.01991-21. Epub 2022 Jan 10. Antimicrob Agents Chemother. 2022. PMID: 35007139 Free PMC article. Review.
A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).
Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T, Sonoyama T, Ichihashi G, Sanaki T, Tsuge Y, Uehara T, Mukae H. Yotsuyanagi H, et al. Among authors: ohmagari n. Medicine (Baltimore). 2023 Feb 22;102(8):e33024. doi: 10.1097/MD.0000000000033024. Medicine (Baltimore). 2023. PMID: 36827007 Free PMC article. Clinical Trial.
Population-level Metagenomics Uncovers Distinct Effects of Multiple Medications on the Human Gut Microbiome.
Nagata N, Nishijima S, Miyoshi-Akiyama T, Kojima Y, Kimura M, Aoki R, Ohsugi M, Ueki K, Miki K, Iwata E, Hayakawa K, Ohmagari N, Oka S, Mizokami M, Itoi T, Kawai T, Uemura N, Hattori M. Nagata N, et al. Among authors: ohmagari n. Gastroenterology. 2022 Oct;163(4):1038-1052. doi: 10.1053/j.gastro.2022.06.070. Epub 2022 Jul 2. Gastroenterology. 2022. PMID: 35788347 Free article.
Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates.
Uraki R, Iida S, Halfmann PJ, Yamayoshi S, Hirata Y, Iwatsuki-Horimoto K, Kiso M, Ito M, Furusawa Y, Ueki H, Sakai-Tagawa Y, Kuroda M, Maemura T, Kim T, Mine S, Iwamoto N, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Wang Z, Ohmagari N, Theiler J, Fischer W, Korber B, Imai M, Suzuki T, Kawaoka Y. Uraki R, et al. Among authors: ohmagari n. Nat Commun. 2023 Mar 23;14(1):1620. doi: 10.1038/s41467-023-37059-x. Nat Commun. 2023. PMID: 36959194 Free PMC article.
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T, Sonoyama T, Fukuhara T, Ichihashi G, Sanaki T, Baba K, Takeda Y, Tsuge Y, Uehara T. Mukae H, et al. Among authors: ohmagari n. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0069722. doi: 10.1128/aac.00697-22. Epub 2022 Sep 13. Antimicrob Agents Chemother. 2022. PMID: 36098519 Free PMC article. Clinical Trial.
Antimicrobials-induced esophageal ulcer.
Ide S, Ishikane M, Ohmagari N. Ide S, et al. Among authors: ohmagari n. IDCases. 2021 Apr 17;24:e01128. doi: 10.1016/j.idcr.2021.e01128. eCollection 2021. IDCases. 2021. PMID: 33981580 Free PMC article. No abstract available.
Duplicate publication.
Matono T, Kato Y, Yotsu R, Ohmagari N. Matono T, et al. Among authors: ohmagari n. Lancet. 2016 Jul 16;388(10041):238. doi: 10.1016/S0140-6736(16)31040-6. Lancet. 2016. PMID: 27479570 No abstract available.
565 results